Boehringer Ingelheim

The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.

NanOlogy Names CEO as Its Tumor-Targeted Cancer Drugs Near Key Regulatory Milestones

by | Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
MORE►
UT Southwestern Spinout Emerges From Stealth With $5.6M to Push ‘First in Class’ Neuroprotective Therapy Into the Clinic
by | Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
MORE►
BioNTX Strengthens Board With Biotech Veteran Jon Weidanz
by | Nov 3, 2023

BioNTX, a leading nonprofit bioscience and healthcare innovation organization in North Texas, has appointed Jon Weidanz to its board of directors. Weidanz brings extensive experience as an immunology researcher, academic leader, biotech entrepreneur, and founder....

MORE►
Follow the Money: Gramercy Raises Nearly $10M; German Pharma Acquires Abexxa Biologics; and Surge Private Equity Invests in Contractor Connect
by | Sep 27, 2021
Plus: Richardson's VOSS Solutions Lands $15M, Acquires Irving's LayerX
MORE►
A Special Thank you to our sponsors

A collaboration of the Dallas Regional Chamber and Dallas Next, Dallas Innovates is an online news platform covering what's new + next in Dallas - Fort Worth innovation.

© Copyright 2026 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners